FIELD NOTE
Abbott Built the Sensor. Google Owns the Screen.
The most consequential thing about a medical device is increasingly not the device.
On Tuesday, Abbott and Google Health announced a multiyear partnership that will route glucose data from Abbott’s Lingo biowearable into the Google Health app, where Google’s Gemini-powered Health Coach will convert it into recommendations on nutrition, activity, sleep, and recovery. The companies also plan a large real-world study integrating continuous glucose, wearable, laboratory, and survey data — one intended, in Abbott’s framing, to shape both future Lingo features and Google’s coaching engine. Integrations begin rolling out later this year.
Read as a product announcement, it’s unremarkable: two large companies improving an app. Read as an architecture decision, it’s a marker for where value in consumer-adjacent medtech is migrating.
Start with what each side brought. Lingo is a regulated product. The FDA cleared it in June 2024 alongside Libre Rio, as an over-the-counter continuous glucose monitor for adults 18 and older who don’t use insulin, and Abbott launched it in the U.S. that September. Every claim about what that sensor measures, and how accurately, went through a 510(k).
Google brought the surface. The Google Health app is the rebuilt Fitbit app, built on a 2021 acquisition that cost $2.1 billion, and Health Coach launched globally on May 19 as the anchor feature of a Google Health Premium subscription — $9.99 a month or $99 a year, and bundled free into Google’s AI Pro and Ultra tiers in more than 30 countries. Google’s own terms for that coach are explicit: the tools are not intended for medical purposes.
So the boundary now runs straight through the product. Abbott’s cleared sensor produces the number. An unregulated wellness coach tells the user what the number means and what to do about it. Nothing about that is unlawful — the general wellness carve-out is well established, and Abbott’s own Lingo app has always offered coaching. But the FDA reviewed a measurement, not an interpretation, and the interpretation is now the part the user actually pays for monthly.
The commercial consequence is sharper than the regulatory one. Abbott gains distribution into an installed base it could never have assembled through hellolingo.com, and a research dataset with real strategic value. What it gives up is the interface. A consumer who lives in the Google Health app and pays Google $9.99 a month has a relationship with Google; Lingo becomes a fourteen-day disposable input to that relationship, purchased on price and accuracy like any other component. Abbott is very good at winning on price and accuracy. That is still a different business than the one it was in on Monday.
Compare Dexcom’s move three weeks earlier. Dexcom was named the first participant in the FDA’s TEMPO pilot for digital health devices, where it will test an AI-enabled glucose program aimed at improving glycemic control. Same technology problem, opposite instinct: pull the AI layer inside the regulatory perimeter, accept the evidentiary burden, and keep the clinical claim — and the customer — in-house.
Neither is obviously right. Platform partnership buys reach immediately and cheaply. Regulated integration is slower and more expensive, but a cleared claim is defensible in a way that a coaching feature isn’t, and it keeps the recurring revenue at home.
What device leaders should take from this week is that the choice is now live in their category too, not just diabetes. Any company whose product generates a continuous data stream will eventually face it: be the sensor inside someone else’s experience, or own the experience and pay the regulatory freight. Abbott just made its call in public. The question worth asking in your next portfolio review is which side of that line your roadmap has quietly already chosen.
SPONSORED BY RŌG HEALTH
Most device companies don't fail on technology. They fail on sequencing.
The free Commercial Readiness Check from RŌG Health takes two minutes and scores your commercialization across six dimensions — where you’re strongest, where you’re exposed, and what to fix first. If you want help closing a gap, it’ll point you to the right starting place.
Want to put your brand in front of 35,000+ medical device and med tech leaders each week? Contact us to learn more about advertising opportunities.
🧭 About The Pathway
The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.
If this was useful, consider subscribing or sharing with a colleague tracking these developments.
Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.